Ramelteon is a selective MT1/MT2-receptor agonist indicated for insomnia treatment. Because it has no depressant effects on the nervous system, it is not expected to affect the control of breathing. The potential effects of ramelteon on apneic and hypopneic events and arterial oxygen saturation (SaO2) in individuals with obstructive sleep apnea were assessed. In this double-blind, randomized, crossover study, 26 adults with mild to moderate obstructive sleep apnea received ramelteon 16 mg and placebo for one night each, with a 5- to 12-day washout period between treatments. Treatments were administered 30 min before habitual bedtime. Respiratory effort was monitored using respiratory inductance plethysmography, SaO2 was measured by pulse oximetry, and sleep onset and duration were measured by polysomnography and post-sleep questionnaire. Post-sleep questionnaire also measured next-day residual effects. The primary measure was apnea–hypopnea index. Apnea–hypopnea index was similar in ramelteon and placebo groups (11.4 vs 11.1, respectively; CI = −2.1, 2.6, P = 0.812). Ramelteon had no effect on the number of central, obstructive, or mixed apnea episodes. No significant differences were observed in SaO2 for the entire night between ramelteon and placebo (95.1 vs 94.7%; P = 0.070). Ramelteon did not meaningfully affect sleep when evaluated by polysomnography and post-sleep questionnaire. Compared with placebo, ramelteon had no significant effect on next-day residual effects. Adverse events were reported by three subjects in the ramelteon group: headache (n = 2) and urinary tract infection (n = 1). No adverse events were reported with placebo. Ramelteon was well-tolerated and, as expected, did not worsen sleep apnea when administered to subjects with mild to moderate obstructive sleep apnea.
Apnea Sleep Hypnotic Ramelteon
This study was funded by Takeda Pharmaceutical Company Limited.
Author Financial Disclosure
Meir Kryger, MD: Consultant, Takeda Pharmaceuticals North America, Inc.
Thomas Roth, PhD: Grants and Consultant, Takeda Pharmaceuticals North America, Inc.
Sherry Wang-Weigand, MD, PhD: Employee, Takeda Global Research & Development Center.
Smith S, Sullivan K, Hopkins W, Douglas J (2004) Frequency of insomnia reports in patients with obstructive sleep apnoea hypopnea syndrome (OSAHS). Sleep Med 5:449–456PubMedCrossRefGoogle Scholar
Krakow B, Melendrez D, Ferreira E, Clark J, Warner TD, Sisley B, Sklar D (2001) Prevalence of insomnia symptoms in patients with sleep-disordered breathing. Chest 120:1923–1929PubMedCrossRefGoogle Scholar
Shepertycky MR, Banno K, Kryger MH (2005) Differences between men and women in the clinical presentation of patients diagnosed with obstructive sleep apnea syndrome. Sleep 28;309–314PubMedGoogle Scholar
George CF (2000) Perspectives on the management of insomnia in patients with chronic respiratory disorders. Sleep 23(Suppl 1):S31–S35PubMedGoogle Scholar
Berry RB, Kouchi K, Bower J, Prosise G, Light RW (1995) Triazolam in patients with obstructive sleep apnea. Am J Respir Crit Care Med 151:450–454PubMedGoogle Scholar
Kato K, Hirai K, Nishiyama K, Uchikawa O, Fukatsu K, Ohkawa S, Kawamata Y, Hinuma S, Miyamoto M (2005) Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist. Neuropharmacology 48:301–310PubMedCrossRefGoogle Scholar
Liu C, Weaver DR, Jin X, Shearman LP, Pieschl RL, Gribkoff VK, Reppert SM (1997) Molecular dissection of two distinct actions of melatonin on the suprachiasmatic circadian clock. Neuron 19:91–102PubMedCrossRefGoogle Scholar
von Gall C, Stehle JH, Weaver DR (2002) Mammalian melatonin receptors: molecular biology and signal transduction. Cell Tissue Res 309:151–162CrossRefGoogle Scholar
Erman M, Seiden D, Zammit G, Sainati S, Zhang J (2006) An efficacy, safety, and dose–response study of ramelteon in patients with chronic primary insomnia. Sleep Med 7:17–24PubMedCrossRefGoogle Scholar
Zammit G, Roth T, Erman M, Sainati S, Weigand S, Zhang J (2005) Double-blind, placebo-controlled polysomnography and outpatient trial to evaluate the efficacy and safety of ramelteon in adult patients with chronic insomnia. Sleep 28:A228–A229Google Scholar
Roth T, Seiden D, Sainati S, Wang-Weigand S, Zhang J, Zee P (2006) Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia. Sleep Med 7:312–318PubMedCrossRefGoogle Scholar
Roth T, Stubbs C, Walsh J (2005) Ramelteon (TAK-375), a selective MT1/MT2-receptor agonist, reduces latency to persistent sleep in a model of transient insomnia related to a novel sleep environment. Sleep 28:303–307PubMedGoogle Scholar
Johnson M, Suess P, Griffiths RR (2006) Ramelteon: a novel hypnotic lacking abuse liability and sedative side effects. Arch Gen Psychiatry 63:1149–1157PubMedCrossRefGoogle Scholar